NEA leads Series A round for Vtesse
Gaithersburg, Maryland-based Vtesse, a drug developer for Niemann-Pick Disease Type C, has received $25 million in Series A funding. New Enterprise Associates led the round with participation from Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments.
8 January 2015•6 mins read
